Y-mabs initiates rolling submission of biologics license application to u.s. fda for naxitamab for treatment of neuroblastoma

Y-mabs initiates rolling submission of biologics license application to u.s. fda for naxitamab for treatment of neuroblastoma.y-mabs therapeutics, inc - upon potential approval, company intends to commercialize naxitamab in u.s..y-mabs therapeutics, inc - has submitted to u.s. fda first portions of its biologics license application for naxitamab.
YMAB Ratings Summary
YMAB Quant Ranking